The ventricular fibrillation market size has grown strongly in recent years. It will grow from $6.51 billion in 2025 to $6.92 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising incidence of sudden cardiac arrest, expansion of emergency medical services, increased availability of defibrillation devices, improvements in cardiopulmonary resuscitation techniques, growth of hospital-based cardiac care.
The ventricular fibrillation market size is expected to see strong growth in the next few years. It will grow to $8.56 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing deployment of public access defibrillators, rising investments in cardiac monitoring technologies, expansion of minimally invasive cardiac treatments, growing integration of ai-driven arrhythmia detection, increased focus on survival outcome improvement. Major trends in the forecast period include increasing adoption of advanced defibrillation technologies, rising use of automated external defibrillators, growing integration of real-time cardiac monitoring, expansion of emergency cardiac care infrastructure, enhanced focus on rapid response systems.
The increasing prevalence of cardiovascular diseases (CVD) is expected to drive the growth of the ventricular fibrillation market in the coming years. Cardiovascular diseases comprise a range of disorders affecting the heart and blood vessels, including coronary artery disease, hypertension, heart failure, and life-threatening arrhythmias such as ventricular fibrillation. The rise in CVD cases is fueled by factors like sedentary lifestyles, poor diet, obesity, smoking, stress, and aging populations. Ventricular fibrillation is one of the most serious complications of CVD, often resulting in sudden cardiac arrest and significantly increasing the risk of death. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, up 4% from 224.4 per 100,000 in 2023. Consequently, the growing burden of cardiovascular diseases is driving the ventricular fibrillation market.
Key players in the ventricular fibrillation market are concentrating on developing advanced technologies, such as sophisticated artificial intelligence (AI) algorithms, to improve the accuracy and efficiency of cardiac diagnostics. AI algorithms are sets of instructions that enable machines to analyze data, perform tasks, and make decisions. These technologies significantly enhance the detection of atrial fibrillation (AF), a major precursor to stroke, by improving the specificity and sensitivity of consumer ECG devices. For example, in January 2024, PulseAI, an Ireland-based medical technology firm, created an advanced AI algorithm aimed at boosting the accuracy and efficiency of ECG diagnostics. This technology leverages machine learning to examine electrocardiogram readings, identifying subtle patterns and anomalies that may signal cardiovascular disease or other conditions. By streamlining analysis and minimizing interpretation errors, PulseAI’s algorithm seeks to enhance patient outcomes and transform cardiac care.
In April 2023, Abbott, a US-based medical device company, acquired Cardiovascular Systems Inc. This acquisition allows Abbott to expand its portfolio of vascular devices, providing more comprehensive solutions for patients with complex cardiovascular conditions. Cardiovascular Systems Inc., based in the US, specializes in developing and commercializing innovative treatments for vascular and coronary diseases.
Major companies operating in the ventricular fibrillation market are Abbott Laboratories, Medtronic plc, GE HealthCare Technologies Inc., Boston Scientific Corporation, Philips Healthcare, St. Jude Medical Inc., Mindray Medical International Limited, ZOLL Medical Corporation, Biotronik, Nihon Kohden Corporation, LivaNova, Fukuda Denshi Co. Ltd., Laerdal Medical Corporation, Schiller AG, Physio-Control, Cardiac Science Corporation, CU Medical Systems Inc., Defibtech LLC, Progetti Srl, HeartSine Technologies.
North America was the largest region in the ventricular fibrillation market in 2025. The regions covered in the ventricular fibrillation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ventricular fibrillation market by increasing costs of imported defibrillators, implantable cardiac devices, monitoring electronics, precision electrodes, and diagnostic equipment. Hospitals and emergency care providers in North America and Europe are most affected due to reliance on imported life-saving devices, while Asia-Pacific faces cost pressures on manufacturing and distribution. These tariffs are contributing to higher treatment and equipment costs and delaying upgrades. However, they are also supporting domestic medical device manufacturing, regional component sourcing, and increased investment in local cardiac care technology development.
The ventricular fibrillation market research report is one of a series of new reports that provides ventricular fibrillation market statistics, including ventricular fibrillation industry global market size, regional shares, competitors with a ventricular fibrillation market share, detailed ventricular fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular fibrillation industry. This ventricular fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ventricular fibrillation is a dangerous heart rhythm disorder characterized by rapid and uncoordinated contractions of the heart's lower chambers (ventricles), resulting in inadequate blood flow throughout the body. This condition is a critical medical emergency that demands immediate intervention and can be fatal if not promptly treated.
The management of ventricular fibrillation involves several approaches, such as cardiopulmonary resuscitation (CPR), defibrillation, medication administration, catheter ablation, and left cardiac sympathetic denervation. CPR, also known as cardiopulmonary resuscitation, is a crucial procedure that includes chest compressions and rescue breaths to restore circulation and breathing in individuals whose heart or breathing has ceased. Various diagnostic methods, including electrocardiograms, blood tests, echocardiograms, electrophysiology studies, and x-rays, are employed across different healthcare settings such as hospitals, ambulatory surgical centers, specialty clinics, and others. These techniques aid in the accurate diagnosis and management of ventricular fibrillation.
The ventricular fibrillation market consists of revenues earned by entities by providing services such as ventricular fibrillation diagnostics, treatment, management, and support services for hospital and clinic applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The ventricular fibrillation market also includes sales of automated external defibrillators, cardiac monitors, and electrocardiogram (ECG) machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The ventricular fibrillation market size is expected to see strong growth in the next few years. It will grow to $8.56 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing deployment of public access defibrillators, rising investments in cardiac monitoring technologies, expansion of minimally invasive cardiac treatments, growing integration of ai-driven arrhythmia detection, increased focus on survival outcome improvement. Major trends in the forecast period include increasing adoption of advanced defibrillation technologies, rising use of automated external defibrillators, growing integration of real-time cardiac monitoring, expansion of emergency cardiac care infrastructure, enhanced focus on rapid response systems.
The increasing prevalence of cardiovascular diseases (CVD) is expected to drive the growth of the ventricular fibrillation market in the coming years. Cardiovascular diseases comprise a range of disorders affecting the heart and blood vessels, including coronary artery disease, hypertension, heart failure, and life-threatening arrhythmias such as ventricular fibrillation. The rise in CVD cases is fueled by factors like sedentary lifestyles, poor diet, obesity, smoking, stress, and aging populations. Ventricular fibrillation is one of the most serious complications of CVD, often resulting in sudden cardiac arrest and significantly increasing the risk of death. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, up 4% from 224.4 per 100,000 in 2023. Consequently, the growing burden of cardiovascular diseases is driving the ventricular fibrillation market.
Key players in the ventricular fibrillation market are concentrating on developing advanced technologies, such as sophisticated artificial intelligence (AI) algorithms, to improve the accuracy and efficiency of cardiac diagnostics. AI algorithms are sets of instructions that enable machines to analyze data, perform tasks, and make decisions. These technologies significantly enhance the detection of atrial fibrillation (AF), a major precursor to stroke, by improving the specificity and sensitivity of consumer ECG devices. For example, in January 2024, PulseAI, an Ireland-based medical technology firm, created an advanced AI algorithm aimed at boosting the accuracy and efficiency of ECG diagnostics. This technology leverages machine learning to examine electrocardiogram readings, identifying subtle patterns and anomalies that may signal cardiovascular disease or other conditions. By streamlining analysis and minimizing interpretation errors, PulseAI’s algorithm seeks to enhance patient outcomes and transform cardiac care.
In April 2023, Abbott, a US-based medical device company, acquired Cardiovascular Systems Inc. This acquisition allows Abbott to expand its portfolio of vascular devices, providing more comprehensive solutions for patients with complex cardiovascular conditions. Cardiovascular Systems Inc., based in the US, specializes in developing and commercializing innovative treatments for vascular and coronary diseases.
Major companies operating in the ventricular fibrillation market are Abbott Laboratories, Medtronic plc, GE HealthCare Technologies Inc., Boston Scientific Corporation, Philips Healthcare, St. Jude Medical Inc., Mindray Medical International Limited, ZOLL Medical Corporation, Biotronik, Nihon Kohden Corporation, LivaNova, Fukuda Denshi Co. Ltd., Laerdal Medical Corporation, Schiller AG, Physio-Control, Cardiac Science Corporation, CU Medical Systems Inc., Defibtech LLC, Progetti Srl, HeartSine Technologies.
North America was the largest region in the ventricular fibrillation market in 2025. The regions covered in the ventricular fibrillation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ventricular fibrillation market by increasing costs of imported defibrillators, implantable cardiac devices, monitoring electronics, precision electrodes, and diagnostic equipment. Hospitals and emergency care providers in North America and Europe are most affected due to reliance on imported life-saving devices, while Asia-Pacific faces cost pressures on manufacturing and distribution. These tariffs are contributing to higher treatment and equipment costs and delaying upgrades. However, they are also supporting domestic medical device manufacturing, regional component sourcing, and increased investment in local cardiac care technology development.
The ventricular fibrillation market research report is one of a series of new reports that provides ventricular fibrillation market statistics, including ventricular fibrillation industry global market size, regional shares, competitors with a ventricular fibrillation market share, detailed ventricular fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular fibrillation industry. This ventricular fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ventricular fibrillation is a dangerous heart rhythm disorder characterized by rapid and uncoordinated contractions of the heart's lower chambers (ventricles), resulting in inadequate blood flow throughout the body. This condition is a critical medical emergency that demands immediate intervention and can be fatal if not promptly treated.
The management of ventricular fibrillation involves several approaches, such as cardiopulmonary resuscitation (CPR), defibrillation, medication administration, catheter ablation, and left cardiac sympathetic denervation. CPR, also known as cardiopulmonary resuscitation, is a crucial procedure that includes chest compressions and rescue breaths to restore circulation and breathing in individuals whose heart or breathing has ceased. Various diagnostic methods, including electrocardiograms, blood tests, echocardiograms, electrophysiology studies, and x-rays, are employed across different healthcare settings such as hospitals, ambulatory surgical centers, specialty clinics, and others. These techniques aid in the accurate diagnosis and management of ventricular fibrillation.
The ventricular fibrillation market consists of revenues earned by entities by providing services such as ventricular fibrillation diagnostics, treatment, management, and support services for hospital and clinic applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The ventricular fibrillation market also includes sales of automated external defibrillators, cardiac monitors, and electrocardiogram (ECG) machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Ventricular Fibrillation Market Characteristics
3. Ventricular Fibrillation Market Supply Chain Analysis
4. Global Ventricular Fibrillation Market Trends and Strategies
5. Ventricular Fibrillation Market Analysis of End Use Industries
7. Global Ventricular Fibrillation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Ventricular Fibrillation Total Addressable Market (TAM) Analysis for the Market
9. Ventricular Fibrillation Market Segmentation
10. Ventricular Fibrillation Market Regional and Country Analysis
11. Asia-Pacific Ventricular Fibrillation Market
12. China Ventricular Fibrillation Market
13. India Ventricular Fibrillation Market
14. Japan Ventricular Fibrillation Market
15. Australia Ventricular Fibrillation Market
16. Indonesia Ventricular Fibrillation Market
17. South Korea Ventricular Fibrillation Market
18. Taiwan Ventricular Fibrillation Market
19. South East Asia Ventricular Fibrillation Market
20. Western Europe Ventricular Fibrillation Market
21. UK Ventricular Fibrillation Market
22. Germany Ventricular Fibrillation Market
23. France Ventricular Fibrillation Market
24. Italy Ventricular Fibrillation Market
25. Spain Ventricular Fibrillation Market
26. Eastern Europe Ventricular Fibrillation Market
27. Russia Ventricular Fibrillation Market
28. North America Ventricular Fibrillation Market
29. USA Ventricular Fibrillation Market
30. Canada Ventricular Fibrillation Market
31. South America Ventricular Fibrillation Market
32. Brazil Ventricular Fibrillation Market
33. Middle East Ventricular Fibrillation Market
34. Africa Ventricular Fibrillation Market
36. Ventricular Fibrillation Market Competitive Landscape and Company Profiles
37. Ventricular Fibrillation Market Other Major and Innovative Companies
40. Ventricular Fibrillation Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Ventricular Fibrillation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses ventricular fibrillation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ventricular fibrillation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ventricular fibrillation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment: Cardiopulmonary Resuscitation (CPR); Defibrillation; Medication; Catheter Ablation; Left Cardiac Sympathetic Denervation2) By Diagnostic Techniques: Electrocardiogram; Electrophysiology Study
3) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-users
Subsegments:
1) By Cardiopulmonary Resuscitation (CPR): Manual Chest Compressions; Mechanical Chest Compressions2) By Defibrillation: Automated External Defibrillators (AEDs); Implantable Cardioverter Defibrillators (ICDs); External Defibrillators
3) By Medication: Antiarrhythmic Drugs; Beta-Blockers; Vasopressors
4) By Catheter Ablation: Radiofrequency Ablation; Cryoablation; Laser Ablation
5) By Left Cardiac Sympathetic Denervation: Surgical Procedure for Sympathetic Denervation; Endoscopic Denervation Techniques
Companies Mentioned: Abbott Laboratories; Medtronic plc; GE HealthCare Technologies Inc.; Boston Scientific Corporation; Philips Healthcare; St. Jude Medical Inc.; Mindray Medical International Limited; ZOLL Medical Corporation; Biotronik; Nihon Kohden Corporation; LivaNova; Fukuda Denshi Co. Ltd.; Laerdal Medical Corporation; Schiller AG; Physio-Control; Cardiac Science Corporation; CU Medical Systems Inc.; Defibtech LLC; Progetti Srl; HeartSine Technologies
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Ventricular Fibrillation market report include:- Abbott Laboratories
- Medtronic plc
- GE HealthCare Technologies Inc.
- Boston Scientific Corporation
- Philips Healthcare
- St. Jude Medical Inc.
- Mindray Medical International Limited
- ZOLL Medical Corporation
- Biotronik
- Nihon Kohden Corporation
- LivaNova
- Fukuda Denshi Co. Ltd.
- Laerdal Medical Corporation
- Schiller AG
- Physio-Control
- Cardiac Science Corporation
- CU Medical Systems Inc.
- Defibtech LLC
- Progetti Srl
- HeartSine Technologies
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.92 Billion |
| Forecasted Market Value ( USD | $ 8.56 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
